- Babu G., (2013). IPAB upholds NATCO’s compulsory license on Nexavar. Business Standard. Retrieved 15 March 2015, from http://www.business-standard.com/article/companies/ipab-upholds-natco-s-compulsory-license-on-nexavar-113030500400_1.html.
Paper not yet in RePEc: Add citation now
- Bhagwati J., (2002). Intellectual property protection and medicines. Retrieved 15 March 2015, from http://www.columbia.edu/~jb38/papers/pdf/FT_Submission_on_IP_Medicines.pdf.
Paper not yet in RePEc: Add citation now
Branstetter L., Fishman R., Foley F., Saggi K., (2011). Does intellectual property rights reform spur industrial development? Journal of International Economics, 83(1), 27–36.
- Buchanan K., (2012, April 23). China: Measures for compulsory licensing of pharmaceuticals updated. Retrieved 15 February 2015, from http://www.loc.gov/lawweb/servlet/lloc_news?disp3_l205403105_text.
Paper not yet in RePEc: Add citation now
- Business Standard (2013, April 22). Pharma R&D: Basic drug research only a part. Business Standard. Retrieved from http://www.business-standard.com/article/companies/pharma-r-d-spend-covers-expenses-much-beyond-drug-research-113042100266_1.html.
Paper not yet in RePEc: Add citation now
- Chaudhuri S., (2012). Multinationals and monopolies: Pharmaceutical industry in India after TRIPS. Economic Political Weekly, XlVII(12), 46–54.
Paper not yet in RePEc: Add citation now
- China Daily (2009, February 12). Bayer sets up R&D Center in China. China Daily. Retrieved 15 February 2014, from http://www.china.org.cn/business/2009-02/12/content_17267872.htm.
Paper not yet in RePEc: Add citation now
- Correa C., (2013). The use of compulsory licenses in Latin America. South Views No. 60, ALAI, América Latina en Movimiento.
Paper not yet in RePEc: Add citation now
- Dey S., (2013, April 22). Pharma R&D: Basic Drug Research only a part. Business Standard. Retrieved 15 March 2015, from http://www.business-standard.com/article/companies/pharma-r-d-spend-covers-expenses-much-beyond-drug-research-113042100266_1.html.
Paper not yet in RePEc: Add citation now
Fosfuri A., (2002). Country risk and international flows of technology: Evidence from the chemical industry. Working Paper 02–25. Departamento de Economia de la Empresa Universidad Carlos III de Madrid, Madrid.
- Goldar B., Gupta I., (2010). Effects of new patents regime on consumers and producers and drugs/medicines in India. Revised Report Submitted to the UNCTAD.
Paper not yet in RePEc: Add citation now
- IFPMA & FIIM. (2011). Technology transfer: A collaborative approach to improve global health. Geneva: International Federation of Pharmaceutical Manufacturers & Associations.
Paper not yet in RePEc: Add citation now
Ivus O., (2010). Do stronger patent rights raise high-tech exports to the developing world? Journal of International Economics, 81(1), 38–47.
Javorcik S., (2004). Does foreign direct investment increase the productivity of domestic firms? In search of spillovers through backward linkages. American Economic Review, 94(3), 605–627.
Kanwar S., (2012). The location of overseas R&D and intellectual property protection. Journal of Development Studies, 48(10), 1453–1469.
Kanwar S., (2013). Innovation, efficiency, productivity and intellectual property rights: Evidence from a BRIC economy. Working Paper No. 230, Centre for Development Economics, Delhi School of Economics.
Klemperer P., (1990). How broad should the scope of patent protection be? RAND Journal of Economics, 21(1), 113–130.
Lerner J., (2002). 150 years of patent protection. American Economic Review, 92(2), 221–225.
Mani S., Nelson R., (2013). TRIPS compliance, national patent regimes and innovation: Evidence and experience from developing countries. Northampton, USA: Edward Elgar Pub.
- McNeil D.G. Jr., (2005, March 24). India alters law on drug patents. The New York Times. Retrieved 15 February 2015, from http://www.nytimes.com/2005/03/24/international/asia/24aids.html?pagewanted=print&position=&_r=0.
Paper not yet in RePEc: Add citation now
Nordhaus W., (1972). The optimum life of a patent: Reply. The American Economic Review, 62 (3), 428–431.
- Park W., Lippoldt D., (2005). International licensing and the strengthening of intellectual property rights in developing countries during the 1990s. OECD Economic Studies, 40(1), 7–48.
Paper not yet in RePEc: Add citation now
Qian Y., (2007). Do national patent laws stimulate domestic innovation in a global patenting environment? A cross-country analysis of pharmaceutical patent protection 1978–2002. Review of Economics and Statistics, 89(3), 436–453.
- Rangnekar D., (2004). Can TRIPs deter innovation? The anticommons and public goods in agricultural research. Paper for the Second International Workshop on ‘Governance of biodiversity as a global public good: Bioprospection, intellectual property rights and traditional knowledge’. Centre de philosophie du droit at the Université catholique de Louvain.
Paper not yet in RePEc: Add citation now
- Stiglitz J., (2006). Making globalization work. New York and London: W.W. Norton and Company Inc.
Paper not yet in RePEc: Add citation now
- The New York Times (2005, March 24). India alters law on drug patents. The New York Times. Retrieved from http://www.nytimes.com/2005/03/24/international/asia/24aids.html?pagewanted=print&position=&_r=0.
Paper not yet in RePEc: Add citation now
Van Dijk T., (1995). Innovation incentives through third-degree price discrimination in a model of patent breadth. Economics Letters, 47(3–4), 431–435.
Vernaz N., Haller G., Girardin F., Huttner B., Combescure C., Dayer P., , . (2013). Patented drug extension strategies on healthcare spending: A cost-evaluation analysis. PLoS Med, 10(6), e1001460. doi:10.1371/journal.pmed.1001460.
- Von Braun J., (n.y.). Use of compulsory licenses selected national experiences. Geneva: UNCTAD. Retrieved 15 March 2015, from http://unctad.org/Sections/dite_totip/docs/tot_ip_0018_en.pdf.
Paper not yet in RePEc: Add citation now
- Winter S., (1989). Patents in complex contexts: Incentives and effectiveness. In Weil V., Snapper J.W., (Eds), Owning scientific and technical information. New Brunswick, NJ: Rutgers University Press.
Paper not yet in RePEc: Add citation now
Yang G., Maskus K., (2001). Intellectual property rights and licensing: An econometric investigation. Weltwirtschaftliches Archiv, 137(1), 58–79.
- Yu P.K., (2005). TRIPs and its discontents. Marquette Intellectual Property Law Review, 10(369), 371–379.
Paper not yet in RePEc: Add citation now